Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

BAX (BCL2-associated X protein)

Written2009-05Hellinida Thomadaki, Andreas Scorilas
Department of Biochemistry, Molecular Biology, University of Athens, 157 01, Panepistimiopolis, Athens, Greece

(Note : for Links provided by Atlas : click)


Alias (NCBI)BCL2L4
HGNC Alias symbBCL2L4
HGNC Previous nameBCL2-associated X protein
 BCL2 associated X protein
LocusID (NCBI) 581
Atlas_Id 128
Location 19q13.33  [Link to chromosome band 19q13]
Location_base_pair Starts at 48954875 and ends at 48961798 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping BAX.png]
Local_order Orientation: Plus Strand.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
BAX (19q13.33)::DHDH (19q13.33)BAX (19q13.33)::HMGA1 (6p21.31)BAX (19q13.33)::MINOS1 (1p36.13)
BAX (19q13.33)::NUCB1 (19q13.33)BAX (19q13.33)::PTPRO (12p12.3)


Description The BAX gene, with 6.939 bases in length, consists of 6 exons and 5 intervening introns.
Transcription The BAX gene is characterized by 5 protein coding transcripts (alpha/psi, beta, delta, epsilon, sigma). Bax-beta encodes the longest isoform (891 bp) of the gene. BAX-alpha/Bax-psi variant is 888 bp in length and codes for a protein isoform that possesses a shorter and different C terminus, as compared with the isoform BAX-beta. The third variant (BAX-delta), which is 741 bp in length, lacks exon 3, whereas it retains the functionally critical C-terminal membrane anchorage region, as well as the BCL2 homology 1 and 2 (BH1 and BH2) domains, although it has a shorter and different C terminus, in comparison with BAX-beta. The fourth identified variant of BAX, which is designated as BAX-epsilon, is 986 bp in length because it contains an extra fragment within the coding region, as well as a distinct 3' coding region and 3' UTR, resulting in a distinct BAX isoform with a shorter and distinct C terminus, as compared with BAX-beta. The fifth identified variant of BAX, BAX-sigma, is 849 bp in length and has also a shorter and different C terminus, when compared with the isoform beta.
Pseudogene Not identified so far.


Note The BAX gene encodes for a 21 kDa protein, named BAX-alpha. It was the first death-inducing member of the BCL2 family to be identified, and it was detected as a protein co-purified with BCL2 in immunoprecipitation studies. The BH3 domain of BAX is essential for its homodimerization and its heterodimerization with BCL2 and BCL-XL. Furthermore, the protein contains a hydrophobic C-terminal region essential for membrane targeting, while BH1 and BH2 domains show homology to pore-forming proteins that contribute to apoptosis. In addition to BAX-alpha, which is the major protein product of the whole gene, BAX undergoes alternative splicing, resulting in the production of distinct protein isoforms. The tumour suppressor p53 is a transcriptional regulator of BAX, since the promoter of the BAX gene possesses four regions with high homology to the consensus p53 binding sites.
Description The BAX belongs to the BCL2 family of proteins. It is composed of 192 amino acids (21184 kDa), with a calculated molecular mass of 21.184 kDa. The BAX protein exists as a monomer, a homodimer, or as a heterodimer with BCL2, E1B 19K protein, BCL2L1 isoform Bcl-X(L), MCL1 and BCL2A1/A1. It also interacts with SH3GLB1 and HN. It contains one BH3 homology domain.
Localisation BAX protein has been reported to be localized in the mitochondria, mitochondrial permeability transition pore complex, mitochondrial outer membrane, endoplasmic reticulum membrane and cytoplasm.
Function BAX protein heterodimerizes either with members of the BCL2 family of proteins or with tyrosine kinases enabling them it to display its proapoptotic function within the cell. It is also implicated in the loss of mitochondrial membrane potential and the release of cytochrome c.
Homology Human BAX shares 99.5% amino acid identity with Pan troglodytes, 97.4% identity with Canis lupus familiaris, 96.4% identity with Bos Taurus, 92.2% identity with Mus musculus, 91.2% identity with Rattus norvegicus and 52.7% identity with Danio rerio. In addition, BAX protein presents high homology to the BCL2 protein, containing the conserved regions BH1, BH2 and BH3.


Note One regulatory type of mutation has been identified according to which a guanine substituting adenosine substitution at position 125 (G125A) in the BAX promoter is associated with higher stage of chronic lymphocytic leukemia (CLL) and failure to respond to treatment in CLL patients. Additionally, 110 SNPs, with uknown clinical association and the following IDs, have been reported in Entrez SNP database: rs62125987, rs62125961, rs61473366, rs61415800, rs60900019, rs59878749, rs59152877, rs57453473, rs57028628, rs56251427, rs56251427, rs55692456, rs55692456, rs36101119, rs36096807, rs36017265, rs35946201, rs35630245, rs35475300, rs35258702, rs34873472, rs34124134, rs34043541, rs28624947, rs28450536, rs12983717, rs12976339, rs12976283, rs12975003, rs11671610, rs11669164, rs11669162, rs11668424, rs11668008, rs11667351, rs11400412, rs11358529, rs11302449, rs10644606, rs7508566, rs7259013, rs7255991, rs7255559, rs4645904, rs4645903, rs4645902, rs4645903, rs4645902, rs4645901, rs4645900, rs4645899, rs4645898, rs4645897, rs4645896, rs4645895, rs4645894, rs4645893, rs4645891, rs4645890, rs4645889, rs4645888, rs4645887, rs4645886, rs4645885, rs4645884, rs4645883, rs4645882, rs4645881, rs4645880, rs4645879, rs4645878, rs4309503, rs3817074, rs3817073, rs2387583, rs1985882, rs1974820, rs1805419, rs1805418, rs1805417, rs1805416, rs1075531, rs1057369, rs1010104, rs1010103, rs1009316, rs1009315, rs905238, rs704243.

Implicated in

Entity Various cancers and diseases
Disease Colorectal cancer, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), B cell chronic lymphocytic leukemia, osteomyelitis.
Prognosis BAX mutations have been found to be associated with positive prognosis in Dukes B2 patients, concerning survival.
The G(-248)A polymorphism in the promoter region of the BAX gene has been associated with reduced BAX expression, advanced disease stage, reduced treatment response and short overall survival in B-cell chronic lymphocytic leukemia (CLL).
Polymorphisms were found for BAX, caused by variation in nucleotide A repeat number at position 360 in the 5'-region of BAX gene. These allelic frequencies of BAX polymorphism were significantly different between males and females and therefore associated with gender-based heamatocrite (HCT) differences.
Substitution of the nucleotide G-->A at position -248 in the BAX gene was more frequent in patients with osteomyelitis and was associated with a longer lifespan of their peripheral blood neutrophils, probably possessing a significant role in the pathogenesis of osteomyelitis.
In cases of malignancies, the concentration of BAX protein in cancer cells is reduced. In addition, p53- deficient mice show reduced BAX levels, ultimately developing T-cell lymphoma.
Reduction of BAX expression levels is negatively associated with many cancers outcome. It is associated with a variety of adverse prognostic factors such as poor response to radio- and chemotherapy, advanced stage, lymph node metastasis, and reduced disease-free and overall survival in variety cancer types, such as colorectal, pancreatic, breast, head and neck, prostate, small cell lung cancer and gynecological (ovarian) malignancies. More specifically, the enhanced expression of BAX protein is a positive prognostic factor for pancreatic cancer and sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. In the case of stage II colon cancer, treated only with surgery, BAX protein expression may be a predictor for prognosis. In ovarian cancer, BAX protein may have a predictive potential in taxane-platinum-treated patients. Moreover, in resected non-small cell lung cancer, low expression of BAX implies poor prognosis. In addition, in patients with advanced esophageal cancer, treated with chemoradiotherapy, reduced expression levels of BAX predict poor prognosis. Low expression of BAX was also significantly associated with poor PFS and OS in nasopharyngeal cancer patients.
In lung cancer, BAX is translocated to the nucleus, enhancing tumour development. Furthermore, mutational analysis of the gene in cases of lung cancer patients revealed the presence of a silent point mutation in codon 184 (TCG>TCA), as well as intronic mutations.
In T cells and endometrium of patients with acute lymphoblastic leukaemia, frameshift mutations have been detected in the BAX gene.
It is a common observation in cases of gastrointestinal cancer, the detection of two specific missense mutations of the BAX gene in codon 169 (Thr > Ala or Thr > Met), which cause inhibition of the proapoptotic activity of the protein and enhance the development of cancer.
Various chemotherapeutic treatments act via up-regulation of the BAX gene to block tumour progression.
BAX is highly expressed in HL-60 but it was found to be hardly expressed in HL-CR cells, a C2-ceramide-resistant HL-60 subline, which has been recently established. These cells showed reduced response to a variety of anticancer drugs including ceramide, doxorubicin, etoposide and cytosine arabinoside.
Hybrid/Mutated Gene Not identified so far.
Abnormal Protein Not identified so far.


Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells.
Antonsson B, Montessuit S, Sanchez B, Martinou JC.
J Biol Chem. 2001 Apr 13;276(15):11615-23. Epub 2001 Jan 2.
PMID 11136736
Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta.
Apte SS, Mattei MG, Olsen BR.
Genomics. 1995 Apr 10;26(3):592-4.
PMID 7607685
Signalling pathways involved in antiproliferative effects of IGFBP-3: a review.
Baxter RC.
Mol Pathol. 2001 Jun;54(3):145-8. (REVIEW)
PMID 11376125
Microsatellite alterations and K-ras, TGFbetaRII, IGFRII and bax mutations in sporadic cancers of the gastrointestinal tract.
Caligo MA, Ghimenti C, Sensi E, Marchetti A, Bertacca G, Giulianotti PG, Fornaciari G, Bevilacqua G.
Oncol Rep. 2000 Nov-Dec;7(6):1371-5.
PMID 11032947
The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients.
Cartron PF, Oliver L, Martin S, Moreau C, LeCabellec MT, Jezequel P, Meflah K, Vallette FM.
Hum Mol Genet. 2002 Mar 15;11(6):675-87.
PMID 11912183
Changes in apoptosis-related pathways in acute myelocytic leukemia.
Casas S, Ollila J, Aventin A, Vihinen M, Sierra J, Knuutila S.
Cancer Genet Cytogenet. 2003 Oct 15;146(2):89-101.
PMID 14553942
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis.
Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR.
Science. 2004 Feb 13;303(5660):1010-4.
PMID 14963330
The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas.
Chou D, Miyashita T, Mohrenweiser HW, Ueki K, Kastury K, Druck T, von Deimling A, Huebner K, Reed JC, Louis DN.
Cancer Genet Cytogenet. 1996 Jun;88(2):136-40.
PMID 8640722
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S.
Blood. 2003 Mar 15;101(6):2125-31. Epub 2002 Nov 7.
PMID 12424199
Significance of mutations in TGFBR2 and BAX in neoplastic progression and patient outcome in sporadic colorectal tumors with high-frequency microsatellite instability.
Fernandez-Peralta AM, Nejda N, Oliart S, Medina V, Azcoita MM, Gonzalez-Aguilera JJ.
Cancer Genet Cytogenet. 2005 Feb;157(1):18-24.
PMID 15676142
Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide.
Floros KV, Thomadaki H, Florou D, Talieri M, Scorilas A.
Ann N Y Acad Sci. 2006 Dec;1090:89-97.
PMID 17384250
bax, but not bcl-2, influences the prognosis of human pancreatic cancer.
Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Buchler MW.
Gut. 1998 Sep;43(3):414-21.
PMID 9863489
Baxbeta: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism.
Fu NY, Sukumaran SK, Kerk SY, Yu VC.
Mol Cell. 2009 Jan 16;33(1):15-29.
PMID 19150424
Tumor response to radiotherapy regulated by endothelial cell apoptosis.
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R.
Science. 2003 May 16;300(5622):1155-9.
PMID 12750523
BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis.
Garrofe-Ochoa X, Melero-Fernandez de Mera RM, Fernandez-Gomez FJ, Ribas J, Jordan J, Boix J.
Mol Cancer Ther. 2008 Dec;7(12):3800-6. Epub 2008 Dec 3.
PMID 19056676
BAX activation is initiated at a novel interaction site.
Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, Walensky LD.
Nature. 2008 Oct 23;455(7216):1076-81.
PMID 18948948
Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.
Jeong SH, Lee HW, Han JH, Kang SY, Choi JH, Jung YM, Choi H, Oh YT, Park KJ, Hwang SC, Sheen SS, Oh YJ, Kim JH, Lim HY.
Jpn J Clin Oncol. 2008 Oct;38(10):661-9. Epub 2008 Sep 4.
PMID 18772168
Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers.
Jung B, Smith EJ, Doctolero RT, Gervaz P, Alonso JC, Miyai K, Keku T, Sandler RS, Carethers JM.
Int J Cancer. 2006 May 15;118(10):2509-13.
PMID 16380996
Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim HY.
Clin Cancer Res. 2007 Jul 15;13(14):4146-53.
PMID 17634542
Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax.
Kang SY, Oh YT, Han JH, Choi JH, Lim HY, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Chun M, Kim CH, Joo HJ.
Neoplasma. 2006;53(5):450-6.
PMID 17013542
Role of Bax and Bak in mitochondrial morphogenesis.
Karbowski M, Norris KL, Cleland MM, Jeong SY, Youle RJ.
Nature. 2006 Oct 12;443(7112):658-62. Epub 2006 Oct 1.
PMID 17035996
Bax deficiency partially corrects interleukin-7 receptor alpha deficiency.
Khaled AR, Li WQ, Huang J, Fry TJ, Khaled AS, Mackall CL, Muegge K, Young HA, Durum SK.
Immunity. 2002 Nov;17(5):561-73.
PMID 12433363
Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.
Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA, Lipton JH.
Blood. 2009 Mar 12;113(11):2517-25. Epub 2009 Jan 13.
PMID 19141860
Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.
Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN.
Semin Cancer Biol. 1993 Dec;4(6):327-32. (REVIEW)
PMID 8142617
Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis.
Kuhlmann T, Glas M, zum Bruch C, Mueller W, Weber A, Zipp F, Bruck W.
J Neuroimmunol. 2002 Aug;129(1-2):154-60.
PMID 12161031
p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
Lahiri O, Harris S, Packham G, Howell M.
Cancer Genet Cytogenet. 2007 Nov;179(1):36-44.
PMID 17981213
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.
Nat Med. 2002 Mar;8(3):274-81.
PMID 11875499
RhoE enhances multidrug resistance of gastric cancer cells by suppressing Bax.
Li K, Lu Y, Liang J, Luo G, Ren G, Wang X, Fan D.
Biochem Biophys Res Commun. 2009 Feb 6;379(2):212-6. Epub 2008 Dec 25.
PMID 19101510
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.
Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, Eng VM, Adelman DM, Simon MC, Ma A, Golden JA, Evan G, Korsmeyer SJ, MacGregor GR, Thompson CB.
Mol Cell. 2000 Dec;6(6):1389-99.
PMID 11163212
Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals.
Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, Laine J, Sakai T, Korsmeyer SJ, Casper RF, Sherr DH, Tilly JL.
Nat Genet. 2001 Aug;28(4):355-60.
PMID 11455387
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX.
Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, de Witte T, Waksman G, Korsmeyer SJ.
Blood. 1998 Apr 15;91(8):2991-7.
PMID 9531611
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
Miyashita T, Reed JC.
Cell. 1995 Jan 27;80(2):293-9.
PMID 7834749
G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
Moshynska O, Moshynskyy I, Misra V, Saxena A.
Oncogene. 2005 Mar 17;24(12):2042-9.
PMID 15688029
Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria.
Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y.
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6.
PMID 9843949
Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone.
Nehls O, Hass HG, Okech T, Zenner S, Hsieh CJ, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Porschen R, Gregor M, Klump B.
Int J Colorectal Dis. 2009 Jun;24(6):655-63. Epub 2009 Feb 17.
PMID 19221769
Bax gene G(-248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis.
Ocana MG, Valle-Garay E, Montes AH, Meana A, Carton JA, Fierer J, Celada A, Asensi V.
Genet Med. 2007 Apr;9(4):249-55.
PMID 17438390
The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes.
Oliveira C, Seruca R, Seixas M, Sobrinho-Simoes M.
Am J Pathol. 1998 Oct;153(4):1211-9. (REVIEW)
PMID 9777952
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
Oltvai ZN, Milliman CL, Korsmeyer SJ.
Cell. 1993 Aug 27;74(4):609-19.
PMID 8358790
The endoplasmic reticulum is a key component of the plasma cell death pathway.
Pelletier N, Casamayor-Palleja M, De Luca K, Mondiere P, Saltel F, Jurdic P, Bella C, Genestier L, Defrance T.
J Immunol. 2006 Feb 1;176(3):1340-7.
PMID 16424160
Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency.
Perez GI, Robles R, Knudson CM, Flaws JA, Korsmeyer SJ, Tilly JL.
Nat Genet. 1999 Feb;21(2):200-3.
PMID 9988273
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M.
Science. 1997 Feb 14;275(5302):967-9.
PMID 9020077
Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance.
Saxena A, Moshynska O, Sankaran K, Viswanathan S, Sheridan DP.
Cancer Lett. 2002 Dec 10;187(1-2):199-205.
PMID 12359369
Bif-1 and Bax expression in cutaneous Merkel cell carcinoma.
Schlauder SM, Calder KB, Khalil FK, Passmore L, Mathew RA, Morgan MB.
J Cutan Pathol. 2009 Jan;36(1):21-5.
PMID 19125733
BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis.
Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ.
Science. 2003 Apr 4;300(5616):135-9. Epub 2003 Mar 6.
PMID 12624178
Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC.
Shimizu S, Narita M, Tsujimoto Y.
Nature. 1999 Jun 3;399(6735):483-7.
PMID 10365962
Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma.
Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P.
Clin Cancer Res. 1999 Nov;5(11):3508-15.
PMID 10589765
Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D, Bentley P, Fegan C.
J Clin Oncol. 2005 Mar 1;23(7):1514-21.
PMID 15735127
Structure of Bax: coregulation of dimer formation and intracellular localization.
Suzuki M, Youle RJ, Tjandra N.
Cell. 2000 Nov 10;103(4):645-54.
PMID 11106734
Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
Thomadaki H, Scorilas A.
Biol Chem. 2008 Nov;389(11):1427-34.
PMID 18783338
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ.
Science. 2001 Apr 27;292(5517):727-30.
PMID 11326099
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC.
Science. 2007 Feb 9;315(5813):856-9.
PMID 17289999
Significant coexpression of GLUT-1, Bcl-xL, and Bax in colorectal cancer.
Wincewicz A, Sulkowska M, Koda M, Kanczuga-Koda L, Witkowska E, Sulkowski S.
Ann N Y Acad Sci. 2007 Jan;1095:53-61.
PMID 17404017
Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T, Bartkowiak J.
Neoplasma. 2005;52(4):318-24.
PMID 16059649
Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents.
Xu ZW, Friess H, Buchler MW, Solioz M.
Cancer Chemother Pharmacol. 2002 Jun;49(6):504-10. Epub 2002 Mar 12.
PMID 12107556
BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.
Yin XM, Oltvai ZN, Korsmeyer SJ.
Nature. 1994 May 26;369(6478):321-3.
PMID 8183370
Sequence-based polymorphisms in members of the apoptosis Bcl-2 gene family and their association with hematocrit level.
Zeng SM, Yankowitz J, Widness JA, Strauss RG.
J Gend Specif Med. 2003;6(4):36-42.
PMID 14714449
Clusterin inhibits apoptosis by interacting with activated Bax.
Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY.
Nat Cell Biol. 2005 Sep;7(9):909-15. Epub 2005 Aug 21.
PMID 16113678
Role of BAX in the apoptotic response to anticancer agents.
Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B.
Science. 2000 Nov 3;290(5493):989-92.
PMID 11062132
TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Ziolkowska-Seta I, Madry R, Kraszewska E, Szymanska T, Timorek A, Rembiszewska A, Kupryjanczyk J.
Gynecol Oncol. 2009 Jan;112(1):179-84. Epub 2008 Oct 19.
PMID 18937971


This paper should be referenced as such :
Thomadaki, H ; Scorilas, A
BAX (BCL2-associated X protein)
Atlas Genet Cytogenet Oncol Haematol. 2010;14(4):356-360.
Free journal version : [ pdf ]   [ DOI ]

Other Leukemias implicated (Data extracted from papers in the Atlas) [ 5 ]
  del(13q) in chronic lymphocytic leukemia
Double Hit Lymphoma (DHL)::Triple Hit Lymphoma (THL)
Follicular lymphoma (FL)
t(2;18)(p11;q21)IGK::BCL2 and IGK::KDSR
t(14;18)(q32;q21) IGH::BCL2::t(2;18)(p11;q21) IGK::BCL2::t(18;22)(q21;q11) IGL/BCL2

External links

HGNC (Hugo)BAX   959
Entrez_Gene (NCBI)BAX    BCL2 associated X, apoptosis regulator
GeneCards (Weizmann)BAX
Ensembl hg19 (Hinxton)ENSG00000087088 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000087088 [Gene_View]  ENSG00000087088 [Sequence]  chr19:48954875-48961798 [Contig_View]  BAX [Vega]
ICGC DataPortalENSG00000087088
TCGA cBioPortalBAX
Genatlas (Paris)BAX
SOURCE (Princeton)BAX
Genetics Home Reference (NIH)BAX
Genomic and cartography
GoldenPath hg38 (UCSC)BAX  -     chr19:48954875-48961798 +  19q13.33   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)BAX  -     19q13.33   [Description]    (hg19-Feb_2009)
GoldenPathBAX - 19q13.33 [CytoView hg19]  BAX - 19q13.33 [CytoView hg38]
Genome Data Viewer NCBIBAX [Mapview hg19]  
OMIM114500   600040   613065   
Gene and transcription
Genbank (Entrez)AF007826 AF247393 AF250190 AI565203 AJ417988
RefSeq transcript (Entrez)NM_001291428 NM_001291429 NM_001291430 NM_001291431 NM_004324 NM_138761 NM_138762 NM_138763 NM_138764
Consensus coding sequences : CCDS (NCBI)BAX
Gene ExpressionBAX [ NCBI-GEO ]   BAX [ EBI - ARRAY_EXPRESS ]   BAX [ SEEK ]   BAX [ MEM ]
Gene Expression Viewer (FireBrowse)BAX [ Firebrowse - Broad ]
GenevisibleExpression of BAX in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)581
GTEX Portal (Tissue expression)BAX
Human Protein AtlasENSG00000087088-BAX [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)BAX
Human Protein Atlas [tissue]ENSG00000087088-BAX [tissue]
Protein Interaction databases
Complex Portal (EBI) CPX-1988 BAX oligomer
Ontologies - Pathways
PubMed499 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:13:10 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us